Healthcare with Confidence
Personalized diagnostics for smarter, safer prostate cancer treatment
If you or your loved one has been diagnosed with prostate cancer, it’s important to make informed decisions based on precise, personalized data.
In Israel, leading oncologists use molecular oncotests — advanced genomic tests that analyze tumor behavior — to choose the best treatment path or to safely recommend active surveillance.
These tests help answer important questions like:
- How aggressive is my prostate cancer?
- Do I need immediate treatment or can I be safely monitored?
- What therapy will work best in my case?
What Are Oncotests and Why Are They Important?
Oncotests (also known as molecular genomic tests or biomarker tests) examine the genetic activity of your prostate cancer. They provide a clearer picture of how fast the tumor is likely to grow, spread, or respond to treatment. These tests go beyond traditional diagnostics like PSA levels, Gleason score, and MRI/CT scans.
Israeli oncologists use oncotests to:
- Predict tumor behavior at an early stage
- Avoid unnecessary treatment when cancer is slow-growing
- Choose the most effective therapy when treatment is needed
- Monitor the risk of recurrence after prostatectomy or radiation
Get Doctor’s Second Opinion Online
When Are Oncotests Used?
Oncotests are especially useful when prostate cancer is still localized — meaning the tumor is limited to the prostate and has not spread to lymph nodes or distant organs. In patients with low or intermediate risk, molecular testing helps determine whether active surveillance is enough or if treatment should begin.
These tests are performed on prostate tissue obtained during a biopsy. Results are combined with standard assessments like PSA level, Gleason score, and tumor staging.
Oncotests Used in Israel Today
Decipher Prostate Test
This oncotest is intended for patients with a low or very low risk factor of prostate cancer in accordance with NCCN guide, who have not yet received treatment for prostate cancer and if doctors are deciding between active surveillance and treatment. It’s also useful for patients with:
- Tumors classified as pT2 or pT3
- Elevated PSA levels
- Uncertain pathology after biopsy
Oncotype DX Prostate
Analyzes a biopsy sample to predict long-term outcomes. Helps determine if and when to switch from observation to active treatment (such as surgery or radiation). Used for:
- Gleason score 6 (low risk)
- Gleason score 7 (intermediate risk)
Prolaris Prostate Test
Supported by NCCN guidelines, this test is used for men with low to favorable intermediate risk who haven’t yet started treatment. Helps assess whether active monitoring is appropriate.
ProMark Prostate
A predictive test for patients with low-risk prostate cancer. It helps evaluate the likelihood of progression, supporting the choice between watchful waiting and immediate therapy.
CTC liquid biopsy test
A modern, non-invasive test that helps doctors better understand your cancer and choose the right treatment. With just a small blood sample, the test checks for circulating tumor cells (CTCs) — cancer cells that have broken away from the main tumor and entered the bloodstream.
This test gives two important pieces of information:
- Confirms the presence and activity of cancer
- Shows which medications are likely to work best for your specific tumor type
By analyzing these tumor cells, the doctor can choose a personalized treatment plan that fits the biology of your cancer — increasing the chances of success and reducing unnecessary side effects.
Why Choose Israel for Oncotesting?
Israeli oncology centers combine global research, cutting-edge technologies, and personalized medicine in prostate cancer care. Our specialists follow the latest international guidelines and participate in ongoing clinical trials. Oncotests in Israel are interpreted by experienced doctors who know how to turn genetic data into practical treatment decisions.
Get a Second Opinion from a Leading Israeli Doctor
We offer online consultations with top prostate cancer specialists in Israel. During the consultation, the doctor will:
- Review your medical history, biopsy, imaging, and lab results
- Evaluate if molecular oncotesting is recommended in your case
- Help you decide between monitoring and active treatment
Ready to Make an Informed Decision?
Contact us today to schedule a remote consultation with a leading prostate cancer expert in Israel.
Let us help you find the safest, most effective approach — tailored to your specific diagnosis.
